Yan Zhou, Mei Li, Bing Zhang, Cheng Yang, Yaling Wang, Shuier Zheng, Lina Tang, Chenliang Zhou, Guowei Qian, Yujing Huang, Wenxi Yu, Hongtao Li, Yonggang Wang, Aina He, Zan Shen, Jianjun Zhang, Xiaoshuang Li, Qingcheng Yang, Haiyan Hu, Yang Yao
BACKGROUND: Cell-based immunotherapy shows the therapeutic potential in sarcomas, in addition to angiogenesis-targeted tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor (ICI). Multi-antigen stimulated cell therapy-I (MASCT-I) technology is a sequential immune cell therapy for cancer, which composes of multiple antigen-loaded dendritic cell (DC) vaccines followed by the adoptive transfer of anti-tumor effector T-cells. METHODS: In this phase 1 study, we assessed MASCT-I plus camrelizumab (an ICI against PD-1) and apatinib (a highly selective TKI targeting VEGFR2) in patients with unresectable recurrent or metastatic bone and soft-tissue sarcoma after at least one line of prior systemic therapy...
November 29, 2023: BMC Medicine